1. Cholestatic hepatitis C after chemotherapy containing rituximab in diffuse large B cell lymphoma.
- Author
-
Pellicelli, Adriano M., D'Ambrosio, Cecilia, Dessanti, Maria L., Villani, Roberto, Fondacaro, Lucia, Miglioresi, Lucia, Grillo, Lucia R., and Andreoli, Arnaldo
- Subjects
RITUXIMAB ,MONOCLONAL antibodies ,B cells ,LYMPHOMAS ,HEPATITIS C virus ,CANCER chemotherapy - Abstract
Rituximab is a chimeric anti-CD20 monoclonal antibody that is a widely used for the treatment of B cells non-Hodgkin lymphoma. The use of chemotherapy regimens containing rituximab in HCV-positive patients with non-Hodgkin lymphoma has been associated with liver dysfunction, but no cases of cholestatic hepatitis C were described. To our knowledge, this is the first case of cholestatic hepatitis C in an HCV-positive patient with diffuse large B-cell lymphoma describes in the literature. We discuss the pathogenetic mechanisms underlying this severe form of hepatitis and describe its evolution after antiviral treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF